NORWOOD IMMUNOLOGY’S STEM CELL STRATEGY
September 30th 2008 01:18
Friday September 26, 2008
Daily news on ASX-listed biotechnology companies
* ASX, BIOTECHS DOWN: OPTISCAN UP 8%, CLINUVEL DOWN 10%
* NORWOOD IMMUNOLOGY’S STEM CELL STRATEGY
* PSIVIDA: ‘REVIEW BACKS PHASE III TRIAL’
* BIO-MELBOURNE WORKSHOP: PRODUCTS AND COMPETITION
To read all these articles in full, subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
NORWOOD IMMUNOLOGY
Norwood Immunology says the Norwood Group has invested $40 million to develop and commercialize stem cells and immune system technologies.
Norwood Abbey said it had a 21 percent shareholding in Norwood Immunology, which announced its updated strategy focusing on the provision of stem cell services and therapies and the licencing and forming of partnerships around intellectual property and therapies based on stem cells, the immune system and immune cell targeting of vaccines.
Norwood Immunology said future directions would include the “development and provision of both veterinary and human stem cell banking and processing services, as well as possible provision of veterinary and human stem cell and immunology-based clinical therapies”.
Norwood Immunology said it was considering “the in-licencing or acquisition of revenue-producing stem cell technologies”.
The London Alternative Investment Market-listed company said it expected to begin earning its first stem cell revenues in 2008-‘09, with the expectation of progressively increasing revenues from the possible provision of stem processing and banking from 2009 onwards.
Norwood Immunology also said it was considering a dual ASX and London AIM listing or an ASX listing.
The company said it had two branches Norwood Stem Cells focused on stem cells and immunology and Norwood Vaccines which includes virosome biologicals.
Full details of the strategic overview are at www.norwoodimmunology.com.
Norwood Abbey was unchanged at 1.4 cents.
subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 28 |
| Vote |
Add To: 
subscribe to this blog